呋喃妥因所致肝损伤的临床特征、结局及HLA风险因素
基于药物性肝损伤网络(DILIN)2004至2020年纳入的78例呋喃妥因所致肝损伤(NTF-DILI)患者,描述其临床特征与结局,并与人群、特发性自身免疫性肝炎及非NTF-DILI对照比较HLA等位基因。肝损伤以肝细胞型为主(69%),长期暴露者更常见桥接纤维化、结节或肝硬化及死亡或肝移植,HLA-DRB1*11:04与NTF-DILI显著相关。
要点
- 长期(≥1年)暴露NTF-DILI者AST>ALT比例达73%,高于短期(≤7天)33%和中期50%。
- 长期暴露者38%存在桥接纤维化、结节或肝硬化,20%有大片或亚大片坏死。
- HLA-DRB1*11:04在NTF-DILI中频率显著高于人群对照(OR 4.29)。
核心结论
- NTF-DILI可导致实质坏死、桥接纤维化、肝硬化及死亡或肝移植,尤其见于长期暴露者,并与HLA-DRB1*11:04相关。
- 为减轻NTF相关严重肝损伤,监管机构应修订处方信息并考虑其他减轻危害的策略。
研究设计与样本
- 研究纳入2004至2020年间DILIN研究中78例确诊、极可能或很可能NTF-DILI个体。
- 将NTF-DILI的HLA等位基因与三组对照比较:人群对照(n=14,001)、特发性自身免疫性肝炎(n=231)和非NTF-DILI(n=661)。
主要发现
- 肝损伤呈肝细胞型者占69%,出现黄疸者占55%。
- 长期暴露(≥1年)44例中AST>ALT比例为73%,高于短期(≤7天)18例的33%和中期(>7天至<365天)16例的50%(p=0.018)。
- 长期暴露组ANA或SMA阳性率为91%,高于短期组44%和中期组50%(p<0.001);皮质类固醇使用率为61%,短期组27%,中期组44%(p=0.06)。
- 长期NTF-DILI中桥接纤维化、结节或肝硬化,或临床及影像学肝硬化证据者占38%,大片或亚大片坏死占20%。
- 短期暴露组无人死亡或接受移植,其他组有7例(12%)死亡或接受移植。
关键数值与推荐
- 长期暴露(≥1年)NTF-DILI者AST>ALT比例为73%,短期(≤7天)为33%,中期(>7天至<365天)为50%(p=0.018)。
- 长期暴露组ANA或SMA阳性率为91%,短期组44%,中期组50%(p<0.001)。
- 长期暴露组皮质类固醇使用率为61%,短期组27%,中期组44%(p=0.06)。
- HLA-DRB1*11:04与NTF-DILI的关联:较人群对照OR 4.29(p=1.15×10-4),较特发性自身免疫性肝炎OR 11.77(p=7.76×10-5),较非NTF-DILI OR 3.34(p=0.003)。
临床怎么用
- 监管机构应修订呋喃妥因处方信息并考虑其他减轻危害的策略。
- 作者指出研究结果对开具呋喃妥因的医师和调配该药的药师具有重要意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Nitrofurantoin (NTF) is widely used for the treatment (short-term) and prevention (long-term) of urinary tract infections. We aimed to describe the clinical characteristics, outcomes, and HLA risk factors for NTF-induced liver injury (NTF-DILI) among individuals enrolled in the Drug Induced Liver Injury Network (DILIN). METHODS: Seventy-eight individuals with definite, highly likely, or probable NTF-DILI were enrolled into DILIN studies between 2004-2020. HLA alleles were compared between NTF-DILI and three control groups: population (n = 14,001), idiopathic autoimmune hepatitis (n = 231), and non-NTF DILI (n = 661). RESULTS: Liver injury was hepatocellular in 69% and icteric in 55%. AST > ALT was more common in the 44 long-exposure (≥1 year) NTF-DILI cases than in the 18 short (≤7 days) and 16 intermediate (>7 to <365 days) exposure cases (73% vs. 33% vs. 50%, respectively, p = 0.018), as was ANA or SMA positivity (91% vs. 44% vs. 50%, respectively, p <0.001), and corticosteroid use (61% vs. 27% vs. 44%, respectively, p = 0.06). In long-term NTF-DILI, bridging fibrosis, nodularity or cirrhosis, or clinical and imaging evidence for cirrhosis were present in 38%, with massive or sub-massive necrosis in 20%. No one in the short-term exposure group died or underwent transplantation, whereas 7 (12%) patients from the other groups died or underwent transplantation. After covariate adjustments, HLA-DRB1∗11:04 was significantly more frequent in NTF-DILI compared to population controls (odds ratio [OR] 4.29, p = 1.15 × 10-4), idiopathic autoimmune hepatitis (OR 11.77, p = 7.76 × 10-5), and non-NTF DILI (OR 3.34, p = 0.003). CONCLUSION: NTF-DILI can result in parenchymal necrosis, bridging fibrosis, cirrhosis, and death or liver transplantation, especially with long-term exposure, and is associated with HLA-DRB1∗11:04. To mitigate against serious liver injury associated with NTF, regulators should revise the prescribing information and consider other mitigation strategies. IMPACT AND IMPLICATIONS: Nitrofurantoin is a recognized cause of drug-induced liver injury (DILI). In this study consisting of a large cohort of well-phenotyped individuals with nitrofurantoin-induced liver injury, two distinct patterns of liver injury were identified: liver injury associated with short-term exposure, which is generally self-limiting, and liver injury associated with long-term exposure, which can lead to advanced fibrosis, cirrhosis and liver failure. HLA DRB1∗11:04 is a risk factor for liver injury due to long-term nitrofurantoin exposure. Our findings are important for regulators as well as physicians prescribing and pharmacists dispensing nitrofurantoin.
引用
- Chalasani N, Li YJ, Dellinger A, et al. Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury. J Hepatol. 2022. PMID: 36152763. doi:10.1016/j.jhep.2022.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。